

Geneviève DURRIEU - Publications 2015-2019

UMR 1027 : Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps

Equipe émergente : Pharmaco-épidémiologie, évaluation de l'utilisation et du risque médicamenteux

Articles dans des revues internationales ou nationales avec comité de lecture ou dans les bases de données internationales

Mise à jour juillet 2019

2019

1. Despas F, Rousseau V, Lafaurie M, De Canecaude C, **Durrieu G**, Montastruc F, Bagheri H, Montastruc JL. [Are Lipid-lowering drugs associated with a risk of cataract? A pharmacovigilance study](#). *Fundam Clin Pharmacol*. 2019 Jun 28. doi: 10.1111/fcp.12496. [Epub ahead of print]
2. **Durrieu G**, Dardonville Q, Clanet M, Montastruc JL. [Cervical dysplasia in a patient with multiple sclerosis treated with natalizumab](#). *Fundam Clin Pharmacol*. 2019 Feb;33(1):125-126. doi: 10.1111/fcp.12394.
3. Kaguelidou F, **Durrieu G**, Clavenna A. [Pharmacoepidemiological research for the development and evaluation of drugs in pediatrics](#). *Therapie*. 2019 Apr;74(2):315-324. doi: 10.1016/j.therap.2018.09.077.
4. Montastruc F, Benevent J, Rousseau V, **Durrieu G**, Sommet A, Montastruc JL. [Risk of diabetes with fibrates and statins: a pharmacoepidemiological study in VigiBase®](#). *Fundam Clin Pharmacol*. 2019 Feb;33(1):108-112. doi: 10.1111/fcp.12406.
5. Montastruc JL, Montastruc F, Benevent J, Lacroix I, **Durrieu G**, Du Plantier JM, Bagheri H, Sommet A, Damase-Michel C. [Tintin in the Land of Drugs: A pharmacological, pharmacovigilance approach](#). *Therapie*. 2019 Jun;74(3):445-447. doi: 10.1016/j.therap.2019.01.002.
6. Nicol C, Moulis F, Bondon-Guitton E, **Durrieu G**, Montastruc JL, Bagheri H. [Does spontaneous adverse drug reactions' reporting differ between different reporters? A study in Toulouse Pharmacovigilance Centre](#). *Therapie*. 2019 Mar 31. pii: S0040-5957(19)30050-2. doi: 10.1016/j.therap.2019.01.008. [Epub ahead of print]

2018

1. Bouquet É, Star K, Jonville-Béra AP, **Durrieu G**. [Pharmacovigilance in pediatrics](#). *Therapie*. 2018 Apr;73(2):171-180. doi: 10.1016/j.therap.2017.11.012.
2. Driot D, Figuet L, Birebent J, Coste S, **Durrieu G**, Jacquot J, Bismuth M. [\[Satisfaction of a pharmacovigilance declaration support network in general practice\]](#). *Therapie*. 2018 Dec;73(6):483-493. doi: 10.1016/j.therap.2018.04.003.
3. **Durrieu G**, Maupiler M, Rousseau V, Chebane L, Montastruc F, Bondon-Guitton E, Montastruc JL. [Frequency and Nature of Adverse Drug Reactions Due to Non-Prescription Drugs in Children: A Retrospective Analysis from the French Pharmacovigilance Database](#). *Paediatr Drugs*. 2018 Feb;20(1):81-87. doi: 10.1007/s40272-017-0255-z.
4. Foch C, Araujo M, Weckel A, Damase-Michel C, Montastruc JL, Benevent J, **Durrieu G**, Lacroix I. [In utero drug exposure and hearing impairment in 2-year-old children A case-control study using the EFEMERIS database](#). *Int J Pediatr Otorhinolaryngol*. 2018 Oct;113:192-197. doi: 10.1016/j.ijporl.2018.07.035.

UMR 1027 - Equipe émergente - Geneviève Durrieu - Publications 2015-2019

5. Kaguelidou F, Kassai Koupai B, **Durrieu G**. [Pediatric pharmacology](#). Therapie. 2018 Apr;73(2):111-112. doi: 10.1016/j.therap.2018.02.003.
6. Montastruc F, Bagheri H, Lacroix I, Damase-Michel C, Chebane L, Rousseau V, Jouanjus E, Lapeyre-Mestre M, **Durrieu G**, Montastruc JL. [Adverse Drug Reaction Reports Received Through the Mobile App, VigiBIP®: A Comparison with Classical Methods of Reporting](#). Drug Saf. 2018 May;41(5):511-514. doi: 10.1007/s40264-017-0630-2.
7. Montastruc F, Benevent J, Chebane L, Rousseau V, **Durrieu G**, Sommet A, Montastruc JL. [Vomiting and constipation associated with tramadol and codeine: a comparative study in VigiBase®](#). Eur J Clin Pharmacol. 2018 Dec;74(12):1673-1674. doi: 10.1007/s00228-018-2536-z.
8. Montastruc F, Benevent J, Touafchia A, Chebane L, Araujo M, Guitton-Bondon E, **Durrieu G**, Arbus C, Schmitt L, Begaud B, Montastruc JL. [Atropinic \(anticholinergic\) burden in antipsychotic-treated patients](#). Fundam Clin Pharmacol. 2018 Feb;32(1):114-119. doi: 10.1111/fcp.12321.
9. Montastruc F, Khosrow-Khavar F, de Germay S, Renoux C, Rousseau V, **Durrieu G**, Montastruc M, Rascol O, Sommet A, Lapeyre-Mestre M, Benevent J, Montastruc JL. [Tamoxifen and the risk of Parkinsonism: a case/non-case study](#). Eur J Clin Pharmacol. 2018 Sep;74(9):1181-1184. doi: 10.1007/s00228-018-2496-3.
10. Moulis F, **Durrieu G**, Lapeyre-Mestre M. [Off-label and unlicensed drug use in children population](#). Therapie. 2018 Apr;73(2):135-149. doi: 10.1016/j.therap.2018.02.002.
11. Moulis F, **Durrieu G**, Masmoudi K, Gervoise Boyer M, Rocher F, Montastruc F, Montastruc JL. [Medication errors with tramadol drops in children](#). Eur J Clin Pharmacol. 2018 Feb;74(2):247-248. doi: 10.1007/s00228-017-2367-3.
12. Moulis F, Rousseau V, Chebane L, Gouverneur A, Gaboriau L, Faillie JL, **Durrieu G**, Montastruc F, Montastruc JL. [Serious adverse drug reactions with sacubitril/valsartan Entresto®: a French pharmacovigilance survey](#). Eur J Clin Pharmacol. 2018 Jul;74(7):983-984. doi: 10.1007/s00228-018-2460-2.
13. Reynolds E, Guénette L, Lexchin J, Cassels A, Wilkes MS, **Durrieu G**, Beaulieu MD, Mintzes B. [Reconciling a "pleasant exchange" with evidence of information bias: A three-country study on pharmaceutical sales visits in primary care](#). Health Policy. 2018 Mar;122(3):250-255. doi: 10.1016/j.healthpol.2018.01.010.

2017

1. Cabarrot A, Montastruc JL, Chebane L, Rousseau V, Bondon-Guitton E, Moulis F, **Durrieu G**, Bagheri H, Montastruc F. [Neurological and digestive bleeding with Direct Oral Anticoagulants versus Vitamin K Antagonists: The differences do not stop there! A pharmacovigilance study](#). Pharmacol Res. 2017 Apr;118:119-120. doi: 10.1016/j.phrs.2016.05.024.
2. **Durrieu G**, Jacquot J, Baudrin D, Mège M, Rousseau V, Bagheri H, Bondon-Guitton E, Abadie D, Montastruc F, Bismuth M, Oustric S, Montastruc JL. [\[Improving adverse drug reaction reporting by general practitioners through clinical research assistants visits\]](#). Therapie. 2017 Jun;72(3):351-355. doi: 10.1016/j.therap.2016.09.004.
3. Linselle M, Sommet A, Bondon-Guitton E, Moulis F, **Durrieu G**, Benevent J, Rousseau V, Chebane L, Bagheri H, Montastruc F, Montastruc JL. [Can drugs induce or aggravate sleep apneas? A case-noncase study in VigiBase®, the WHO pharmacovigilance database](#). Fundam Clin Pharmacol. 2017 Jun;31(3):359-366. doi: 10.1111/fcp.

4. Montastruc F, Benevent J, Rousseau V, Chebane L, Bondon-Guitton E, **Durrieu G**, Montastruc JL, Sommet A. [Statins and diabetes: is there any difference between the different statins?](#) *Pharmacoepidemiol Drug Saf.* 2017 Oct;26(10):1296-1297. doi: 10.1002/pds.4296.
5. Montastruc J, Marque P, Moulis F, Bourg V, Lambert V, **Durrieu G**, Montastruc JL, Montastruc F. [Adverse drug reactions of botulinum neurotoxin type A in children with cerebral palsy: a pharmaco-epidemiological study in VigiBase.](#) *Dev Med Child Neurol.* 2017 Mar;59(3):329-334. doi: 10.1111/dmcn.13286.
6. Ojero-Senard A, Benevent J, Bondon-Guitton E, **Durrieu G**, Chebane L, Araujo M, Montastruc F, Montastruc JL. [A comparative study of QT prolongation with serotonin reuptake inhibitors.](#) *Psychopharmacology (Berl).* 2017 Oct;234(20):3075-3081. doi: 10.1007/s00213-017-4685-7. *Paediatr Drugs.* 2017 Oct;234(20):3075-3081. doi: 10.1007/s00213-017-4685-7.

2016

1. Cabarrot A, Montastruc JL, Chebane L, Rousseau V, Bondon-Guitton E, Moulis F, **Durrieu G**, Bagheri H, Montastruc F. [Neurological and digestive bleeding with Direct Oral Anticoagulants versus Vitamin K Antagonists: The differences do not stop there! A pharmacovigilance study.](#) *Pharmacol Res.* 2016 Jun 2. pii: S1043-6618(16)30493-5. doi: 10.1016/j.phrs.2016.05.024.
2. De Gernay S, Montastruc JL, Rousseau V, Chebane L, Bondon-Guitton E, Moulis F, **Durrieu G**, Bagheri H, Rascol O, Pariente A, Bégaud B, Montastruc F. [Atropinic \(Anticholinergic\) Burden in Parkinson's Disease.](#) *Mov Disord.* 2016 May;31(5):632-6. doi: 10.1002/mds.26595.
3. **Durrieu G**, Jacquot J, Mège M, Bondon-Guitton E, Rousseau V, Montastruc F, Montastruc JL. [Completeness of Spontaneous Adverse Drug Reaction Reports Sent by General Practitioners to a Regional Pharmacovigilance Centre: A Descriptive Study.](#) *Drug Saf.* 2016 Dec;39(12):1189-1195.
4. Montastruc JL, Bondon-Guitton E, Abadie D, Lacroix I, Berreni A, Pugnet G, **Durrieu G**, Sailler L, Giroud JP, Damase-Michel C, Montastruc F. [Pharmacovigilance, risks and adverse effects of self-medication.](#) *Therapie.* 2016 Apr;71(2):257-62. doi: 10.1016/j.therap.2016.02.012.

2015

1. Abadie D, Chebane L, Bert M, **Durrieu G**, Montastruc JL. [Addendum to: Online Reporting of Adverse Drug Reactions: A Study from a French Regional Pharmacovigilance Center - Thérapie 69 \(5\): 395-400 \(2014\) DOI: 10.2515/therapie/2014035.](#) *Therapie.* 2015 Oct 16. [Epub ahead of print]
2. Berreni A, Montastruc F, Bondon-Guitton E, Rousseau V, Abadie D, **Durrieu G**, Chebane L, Giroud JP, Bagheri H, Montastruc JL. [Adverse drug reactions to self-medication: a study in a pharmacovigilance database.](#) *Fundam Clin Pharmacol.* 2015 Oct;29(5):517-20. doi: 10.1111/fcp.12140.
3. Montastruc JL, Rousseau V, Chebane L, Abadie D, Bondon-Guitton E, **Durrieu G**, Montastruc F, Bagheri H. [Hemorrhagic effects of oral anticoagulants: a comparative study between vitamin K antagonists \(VKA\) and direct oral anticoagulants \(DOA\).](#) *Eur J Clin Pharmacol.* 2015 Oct;71(10):1283-4. doi: 10.1007/s00228-015-1905-0.
4. Palmaro A, Bissuel R, Renaud N, **Durrieu G**, Escourrou B, Oustric S, Montastruc JL, Lapeyre-Mestre M. [Off-label prescribing in pediatric outpatients.](#) *Pediatrics.* 2015 Jan;135(1):49-58. doi: 10.1542/peds.2014-0764.